←Crohn Disease
Study register · detail Beobachtungsstudie (retrospektive Fragebogen-Erhebung) · Crohn Disease · 2014

Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohnʼs Disease

Storr et al. ·Inflammatory Bowel Diseases Impact 2.3
Mixed GRADE Low 203 citations
Samplen = 313 Pat.
DurationJuly 2008 to March 2009
EndpointSurgery rate / hospitalization
Blindingn.a.
DesignBeobachtungsstudie (retrospektive Fragebogen-Erhebung)
Cannabinoidvollspektrum
Routeinhalativ
Key finding

Cannabis improves subjective IBD symptoms, but is associated with a higher risk of surgery in Crohn's disease.

Summary

Questionnaire survey of n=313 IBD patients (University of Calgary 2008–2009); 17.6% used cannabis specifically for symptom relief. Subjectively reported improvements: abdominal pain (83.9%), cramping (76.8%), joint pain (48.2%), diarrhea (28.6%). NOTE: Cannabis use >6 months was a strong predictor of surgery in Crohn's disease (OR=5.03, 95% CI 1.45–17.46) after adjustment for demographic factors. Not a predictor of hospitalization.

P
PopulationAdults with chronic inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis), n=313, consecutively recruited at the University of Calgary
I
InterventionSelf-administered cannabis use for symptom relief in IBD (predominantly inhaled, 96,4%)
O
OutcomeCannabis subjectively improved abdominal pain (83,9%), cramping (76,8%), joint pain (48,2%) and diarrhea (28,6%); cannabis use >6 months was a strong predictor of surgical intervention in Crohn's disease (OR=5,03; 95%-CI 1,45–17,46)
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Mixed
Citations / year ★★★★★
Authors
Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN
DOI 10.1097/01.mib.0000440982.79036.d6↗
Design: Beobachtungsstudie (retrospektive Fragebogen-Erhebung)
Share
Indication
Further studies on Crohn Disease
All studies →
S Mack et al. · 2019 · Gastroenterology
73 citations
Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.
Unclear Systematic Review

Canadian Association of Gastroenterology Clinical Practice Guideline für pädiatrischen Morbus Crohn; 25 Statements nach GRADE-Methodik. Empfiehlt gegen Cannabis in jeder Rolle bei pädiatrischem Morbus Crohn. Systematische Evidenzbewertung durch iterativen Konsensusprozess.

10.1053/j.gastro.2019.03.022 View study →
A Naftali et al. · 2021 · Journal of Crohn's and Colitis
77 citations
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial
Mixed RCT (double-blind, placebo-controlled)

Naftali et al. 2021 — doppelblinde RCT, n=56 Morbus-Crohn-Patienten (30 Cannabis, 26 Placebo); CBD-reiches Cannabisöl (160/40 mg/ml CBD/THC) vs. Placebo über 8 Wochen. CDAI-Reduktion signifikant in Cannabis-Gruppe (Median 282→166) vs. Placebo (264→237), p<0.05. Quality-of-Life-Score verbessert (74→91 Cannabis vs. 74→75 Placebo, p=0.004). KEINE signifikante Änderung bei endoskopischem Score (SES-CD) oder Entzündungsmarkern (CRP, Calprotectin, p=0.75). Klinische Remission ohne endoskopische oder inflammatorische Verbesserung; gut verträglich.

10.1093/ecco-jcc/jjab069 View study →
A Abrams et al. · 2018 · European Journal of Internal Medicine
294 citations
The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report
Mixed Narrative Review

Update des National Academies of Sciences-Berichts zu therapeutischen Cannabis-Effekten (Abrams 2018); konsolidiert Evidenz für chronischen Schmerz, MS-Spastik, Chemotherapie-induzierte Übelkeit; für Morbus Crohn wird limitierte Evidenz für symptomatische Linderung bei fehlender antiinflammatorischer Wirkung zusammengefasst.

10.1016/j.ejim.2018.01.003 View study →

The impediment to action advances action. — Marcus Aurelius